BioTuesdays

Tag - Jason McCarthy

Markets

Maxim starts Clene at buy; PT $18

Maxim Group launched coverage of Clene (NASDAQ:CLNN) with a “buy” rating and $18 price target. The stock closed at $8.95 on May 19. Clene is a clinical-stage company developing CNM-Au8, an oral, clean-surfaced faceted...

May 20, 2021
Markets

Maxim ups Annovis Bio PT to $45 from $12

Maxim Group raised its price target for Annovis Bio (NYSE American: ANVS) to $45 from $12, citing upcoming Phase 2a data evaluating ANVS401 in Alzheimer’s disease (AD) and Parkinson’s disease (PD) patients. The stock...

May 13, 2021
Markets

Maxim doubles BioLineRx PT to $10 from $5

Maxim Group raised its price target for BioLineRx (NASDAQ:BLRX) to $10 from $5 on positive top-line data from the company’s Phase 3 GENESIS trial. The stock was quoted at $5.30, up $2.11, in afternoon trading on...

May 4, 2021
cohbar-logo
Markets

Maxim starts CohBar at buy; PT $3

Maxim Group initiated coverage of CohBar (NASDAQ:CXBR), which is developing a therapeutic platform based on mitochondrial-derived peptides, with a “buy” rating and price target of $3. The stock closed at $1.24 on April...

April 23, 2021
Markets

Maxim ups Cerecor to buy from hold; PT $7

Maxim Group upgraded Cerecor (NASDAQ:CERC) to “buy” from “hold” with a price target of $7, citing an advancing pipeline of assets and the potential for multiple priority review vouchers (PRVs). The stock closed at $2.34...

April 21, 2021
Mesoblast Logo
Markets

Maxim ups Mesoblast to buy from hold; PT $18

Maxim Group upgraded Mesoblast (NASDAQ:MESO) to “buy” from “hold” with a price target of $18, citing the totality of the company’s cell therapy data, which are “quite good.” The stock closed at $8.45 on April 6...

April 7, 2021
Amryt-Logo
Markets

Maxim starts Amryt Pharma at buy; PT $27

Maxim Group launched coverage of Amryt Pharma plc (NASDAQ, AIM:AMYT) with a “buy” rating and $27 price target. The stock closed at $13.84 on March 30. Amryt is a commercial rare disease company globally marketing...

March 31, 2021
Markets

Maxim cuts Co-Diagnostics to hold; removes PT

Maxim Group downgraded Co-Diagnostics (NASDAQ:CODX) to “hold” from “buy” and removed its priced target, citing COVID-19 testing and revenue growth, which appear “to have peaked.” The stock closed at $9.70 on March 26...

March 29, 2021
Medicinova inc logo
Markets

Maxim starts MediciNova at buy; PT $15

Maxim Group launched coverage of MediciNova (NASDAQ:MNOV) with a “buy” rating and $15 price target. The stock closed at $5.68 on March 9. MediciNova is developing MN-166 for neurodegenerative diseases, glioblastoma...

March 10, 2021